Brief: Aravive Announces Positive Initial Results From Phase 1B Portion Of The Phase1b/2 Study Of Avb-500 In Combination With Cabozantinib In Clear Cell Renal Carcinoma

Aravive

24/06/2021 12:38

June 24 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE ANNOUNCES POSITIVE INITIAL RESULTS FROM PHASE 1B
PORTION
OF THE PHASE1B/2 STUDY OF AVB-500 IN COMBINATION WITH
CABOZANTINIB IN CLEAR CELL RENAL CARCINOMA
    * ARAVIVE INC - AVB-500 WAS WELL TOLERATED WITH NO
UNEXPECTED
FINDINGS
    * ARAVIVE INC - PLANS TO EXPAND DOSING OF 15MG/KG OF AVB-500
TO AN
ADDITIONAL THREE PATIENTS

Source text for Eikon:  ID:nGNX8VKl2B 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))